| Case report: Fulminant celiac disease with combination immune checkpoint therapy AS Falade, KL Reynolds, L Zubiri, V Deshpande, FJ Fintelmann, ... Frontiers in immunology 13, 871452, 2022 | 11 | 2022 |
| PD-1 Blockade before autologous stem cell transplantation improves outcomes in relapsed/refractory classic Hodgkin lymphoma: results from a multicenter cohort SH Desai, RW Merryman, H Shah, LD Pederson, SM Geyer, N Ganesan, ... Blood 142, 182, 2023 | 8 | 2023 |
| Efficacy of brentuximab vedotin maintenance therapy following autologous stem cell transplantation in patients with relapsed/refractory classical Hodgkin lymphoma with and … AS Falade, RA Redd, H Shah, K Baron, S Iyengar, SH Desai, SM Ansell, ... Blood 142, 3062, 2023 | 4 | 2023 |
| Enhancing precision in detecting severe immune-related adverse events: Comparative analysis of large language models and international classification of disease codes in … VH Sun, JC Heemelaar, I Hadzic, VK Raghu, CY Wu, L Zubiri, A Ghamari, ... Journal of Clinical Oncology 42 (35), 4134-4144, 2024 | 3 | 2024 |
| Immune-related adverse events requiring hospitalization in patients with lung cancer: implications and insights A Falade, L Zubiri, CY Wu, K Perlman, J Sun, N Hathaway, K Grealish, ... The Oncologist 29 (11), e1615-e1620, 2024 | 1 | 2024 |
| Learning about and living with toxicity: a qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers AS Falade, MC Boulanger, K Hsu, R Sarathy, R Fadden, KL Reynolds, ... Supportive Care in Cancer 32 (10), 684, 2024 | 1 | 2024 |
| Outcomes for patients with classical Hodgkin lymphoma who relapse after autologous stem cell transplant in the era of novel therapies R Stuver, E Drill, N Ganesan, K Baron, E Casper, T Chang, SH Desai, ... Blood 142, 3069, 2023 | 1 | 2023 |
| Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma S Kambhampati, RW Merryman, Y Wang, E Bezerra, T Voorhees, ... Blood 142, 3511, 2023 | 1 | 2023 |
| Global health training opportunities during pediatric hematology/oncology fellowship: Results from a survey of program leaders PR Hornstein, AS Falade, SA Triedman, LE Lehmann, TA Fadelu Pediatric Blood & Cancer 72 (1), e31375, 2025 | | 2025 |
| Using context‐specific evidence to inform resource‐stratified cancer guidelines: A call for a new approach GC Buckle, R DeBoer, MJ Xu, A Mrema, F Rubagumya, J Velloza, ... Cancer, 2025 | | 2025 |
| Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma SK Thiruvengadam, R Merryman, Y Wang, C Gaulin, E Bezerra, ... American journal of hematology, 2024 | | 2024 |
| Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting GT Baek, G Varma, S Yamshon, H van Besien, NL Bartlett, MP Watkins, ... Blood 144, 4431, 2024 | | 2024 |
| Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma S Kambhampati, RW Merryman, Y Wang, C Gaulin, E Bezerra, ... Blood 144, 524, 2024 | | 2024 |
| Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin … G Varma, MC Rosenberg, EC Agbadiba, AH Yeung, AS Falade, ... Blood 144, 4425, 2024 | | 2024 |
| Clinical Trials in Gastroesophageal Cancers: An Analysis of the Global Landscape of Interventional Trials From ClinicalTrials. gov AS Falade, O Adeoye, K Van Loon, GC Buckle JCO Global Oncology 10, e2400169, 2024 | | 2024 |
| Survey of Hematology/Oncology Program Leaders on Equity and Global Health Opportunities for Fellows AS Falade, PR Hornstein, SE Slater, SA Triedman, LA Buswell, TA Fadelu JCO Global Oncology 10, e2400254, 2024 | | 2024 |
| Global Landscape of Phase III Interventional Clinical Trials in Colorectal Cancer O Adeoye, A Falade, A Paciorek, G Buckle JCO Global Oncology 10 (Supplement_1), 88-88, 2024 | | 2024 |
| Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative Study MC Boulanger, AS Falade, K Hsu, RK Sommer, A Zhou, R Sarathy, ... JCO Oncology Practice, OP. 24.00299, 2024 | | 2024 |
| Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience. CY Wu, L Zubiri, SJ Rouhani, RD Merkin, A Holt, AS Falade, K Grealish, ... Journal of Clinical Oncology 42 (16_suppl), e14609-e14609, 2024 | | 2024 |
| Outcomes of Patients with ALK+ Anaplastic Large Cell Lymphoma Refractory or Relapsed after Frontline Chemotherapy M Sorrell, A Ip, R Stuver, GL Shah, A Crawford, D Jagadeesh, B Matia, ... Transplantation and Cellular Therapy 30 (2), S363-S364, 2024 | | 2024 |
